Fig. 1From: 68Ga-PSMA ligand PET/CT in patients with prostate cancer: How we review and reportMaximum intensity protection (MIP) images of a patient with physiological distribution of 68Ga-PSMA ligand. Accumulation is seen in lacrimal and salivary glands, nasal mucosa, liver, spleen, bowel, kidneys and bladderBack to article page